Equities

Pacira Biosciences Inc

Pacira Biosciences Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)17.24
  • Today's Change-0.46 / -2.60%
  • Shares traded756.24k
  • 1 Year change-42.38%
  • Beta0.8041
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Pacira Biosciences Inc had relatively flat revenues (666.82m to 674.98m), though the company grew net income 163.72% from 15.91m to 41.96m.
Gross margin74.35%
Net profit margin-13.06%
Operating margin-8.26%
Return on assets-5.94%
Return on equity-11.48%
Return on investment-6.83%
More ▼

Cash flow in USDView more

In 2023, Pacira Biosciences Inc increased its cash reserves by 47.21%, or 49.16m. The company earned 154.65m from its operations for a Cash Flow Margin of 22.91%. In addition the company generated 77.54m cash from investing, though they paid out 183.03m more in financing than they received.
Cash flow per share-0.2734
Price/Cash flow per share--
Book value per share16.24
Tangible book value per share6.70
More ▼

Balance sheet in USDView more

Pacira Biosciences Inc has a Debt to Total Capital ratio of 43.93%, a lower figure than the previous year's 62.05%.
Current ratio2.25
Quick ratio1.89
Total debt/total equity0.7836
Total debt/total capital0.4393
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.